- Home
- VANI vs FBRX Comparison
VANI vs FBRX Comparison
Compare VANI & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VANI
- FBRX
- Stock Information
- Founded
- VANI 1998
- FBRX N/A
- Country
- VANI United States
- FBRX United States
- Employees
- VANI 36
- FBRX N/A
- Industry
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- VANI Health Care
- FBRX Health Care
- Exchange
- VANI Nasdaq
- FBRX Nasdaq
- Market Cap
- VANI 75.2M
- FBRX 69.7M
- IPO Year
- VANI 2014
- FBRX N/A
- Fundamental
- Price
- VANI $1.40
- FBRX $10.55
- Analyst Decision
- VANI Strong Buy
- FBRX Strong Buy
- Analyst Count
- VANI 1
- FBRX 2
- Target Price
- VANI $4.00
- FBRX $61.00
- AVG Volume (30 Days)
- VANI 134.3K
- FBRX 185.0K
- Earning Date
- VANI 08-12-2025
- FBRX 08-13-2025
- Dividend Yield
- VANI N/A
- FBRX N/A
- EPS Growth
- VANI N/A
- FBRX N/A
- EPS
- VANI N/A
- FBRX N/A
- Revenue
- VANI N/A
- FBRX N/A
- Revenue This Year
- VANI N/A
- FBRX N/A
- Revenue Next Year
- VANI N/A
- FBRX N/A
- P/E Ratio
- VANI N/A
- FBRX N/A
- Revenue Growth
- VANI N/A
- FBRX N/A
- 52 Week Low
- VANI $0.91
- FBRX $4.11
- 52 Week High
- VANI $1.50
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- VANI 74.26
- FBRX 44.73
- Support Level
- VANI $1.26
- FBRX $10.15
- Resistance Level
- VANI $1.30
- FBRX $13.20
- Average True Range (ATR)
- VANI 0.06
- FBRX 1.89
- MACD
- VANI 0.00
- FBRX -0.38
- Stochastic Oscillator
- VANI 69.70
- FBRX 4.72
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).